Improving understanding and treatment of prostate cancer
Official title: DF/HCC Prostate SPORE
Funded at Dana-Farber Cancer Inst · NIH-10916194 · Data updated 2026-11-12
This study is all about improving how we understand and treat prostate cancer, helping patients by finding better ways to fight the disease and personalize their treatment based on their unique tumors.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $2,393,890 |
| NIH project number | 5P50CA272390-02 |
| Project ID | NIH-10916194 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are individuals diagnosed with high-risk or advanced prostate cancer.
✕Less likely to help
Patients with early-stage prostate cancer or those not diagnosed with prostate cancer may not benefit from this research.
What this research studies
The Dana-Farber/Harvard Cancer Center Prostate SPORE focuses on enhancing the understanding and treatment of prostate cancer through a collaborative and translational approach. It includes multiple projects that investigate how tumors respond to treatments, develop new strategies to combat treatment resistance, and identify biomarkers for localized prostate cancer. By leveraging patient tumor specimens and advanced computational techniques, the research aims to provide personalized treatment options for patients. This initiative also includes programs for career enhancement and developmental research to foster innovation in prostate cancer care.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and improved outcomes for patients with prostate cancer.
How similar studies have gone: Previous research in prostate cancer has shown promising results with similar translational approaches, indicating potential for success in this initiative.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Beltran, Himisha — Dana-Farber Cancer Inst
- Study coordinator: Beltran, Himisha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.